| First Author | Ota A | Year | 2009 |
| Journal | Exp Hematol | Volume | 37 |
| Issue | 4 | Pages | 525-31 |
| PubMed ID | 19302923 | Mgi Jnum | J:147034 |
| Mgi Id | MGI:3839154 | Doi | 10.1016/j.exphem.2008.12.006 |
| Citation | Ota A, et al. (2009) Upregulation of plasma CCL8 in mouse model of graft-vs-host disease. Exp Hematol 37(4):525-31 |
| abstractText | OBJECTIVE: Using a proteomic approach, we recently identified plasma CCL8 as a potential biomarker for diagnosis of graft-vs-host-disease (GVHD) in mice as well as humans. Because mass spectrometric analysis is only semi-quantitative, a quantitative method of measuring plasma CCL8 levels in mice is needed. MATERIALS AND METHODS: We established an enzyme-linked immunosorbent assay for the quantitative measurement of CCL8 concentrations in mouse plasma. RESULTS: Our newly established enzyme-linked immunosorbent assay revealed that the plasma CCL8 concentrations (mean +/- standard error; n=12) were 1287+/-55.7 ng/mL and 1604+/-110.8 ng/mL on days 7 and 14 after allogeneic bone marrow transplantation (BMT), respectively, while the plasma concentrations was 316.6+/-16.3 ng/mL on day 7 after syngeneic BMT. A Western blotting analysis also showed a difference in the plasma CCL8 levels between the allogeneic and syngeneic BMT groups, as did clinical GVHD scores. Neither lipopolysaccharide nor poly(I:C) elevated the plasma CCL8 concentrations, although a dramatic increase in interleukin-6 was detected after both treatments. CONCLUSION: An elevated plasma CCL8 concentration may be a promising plasma marker for GVHD in mouse models. |
